Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

OBJECTIVES: To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in patients with rheumatoid arthritis (RA) for an additional six infusions. METHODS: This open-label extension study recr...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Rheum Dis
Glavni autori: Yoo, Dae Hyun, Prodanovic, Nenad, Jaworski, Janusz, Miranda, Pedro, Ramiterre, Edgar, Lanzon, Allan, Baranauskaite, Asta, Wiland, Piotr, Abud-Mendoza, Carlos, Oparanov, Boycho, Smiyan, Svitlana, Kim, HoUng, Lee, Sang Joon, Kim, SuYeon, Park, Won
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2017
Teme:
Clinical and Epidemiological Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5284338/
https://ncbi.nlm.nih.gov/pubmed/27130908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2015-208786
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items